Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Study of INV-202 in Patients With Obesity and Metabolic Syndrome
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Inversago Pharma Inc.
- Target Recruit Count
- 243
- Registration Number
- NCT05891834
- Locations
- 🇨🇦
Office of David H. Shu, MD, New Westminster, British Colombia, Canada
🇨🇦Centricity Research -New Minas, New Minas, Nova Scotia, Canada
🇨🇦Aggarwal and Associates, Limited, Brampton, Ontario, Canada
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Inversago Pharma Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT05514548
- Locations
- 🇺🇸
National Institute of Clinical Research, Inc., Garden Grove, California, United States
🇺🇸National Institute of Clinical Research, Inc - Pomona, Pomona, California, United States
🇺🇸Central Coast Nephrology, Salinas, California, United States
A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Inversago Pharma Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05282446
- Locations
- 🇨🇦
Syneos Health Clinique Inc, Québec, Quebec, Canada
Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Inversago Pharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04531150
- Locations
- 🇨🇦
Altasciences, Montreal, Quebec, Canada
News
No news found